Brain HealthPlasma p-tau217 Blood Test Predicts 5- and 10-Year Risk of Cognitive Decline
Alzheimer disease changes in the brain can begin years before memory problems appear, yet some people with these changes never become symptomatic. Researchers from Mayo Clinic and the Alzheimer's Disease Neuroimaging Initiative followed 2,178 cognitively healthy adults aged 60 to 90 to see how a blood marker called plasma p-tau217 relates to later decline. They combined the marker with age, sex, and APOE ε4 gene status to estimate actual risk over 5 and 10 years. For a 75-year-old, going from a low to a high p-tau217 level raised 5-year risk of mild cognitive impairment from 7% to 17% and 10-year risk from 15% to 35%. Age mattered a great deal too: at a high p-tau217 level, 10-year risk was 17% at age 65 but 66% at age 85. The findings suggest a single blood test can give individualized risk estimates, useful for prognosis and for selecting people for prevention trials.